Virus roundup … 

Sign up for the free Daily Report email – local news about the people, companies and issues that impact business impact business in Baton Rouge and beyond.

• We have faced viral threats before, including pandemics, yet the world does not shut down for every new infection or flu season. So what is it about this coronavirus? What are the quirks of its biology that pose a unique threat to our bodies and our lives? Read a recent explainer from BBC News that aims to clarify questions about the virus based on research. 

• Pfizer’s late-stage coronavirus vaccine trial has enrolled more than 42,000 volunteers, the company announced Tuesday when it released a mixed third-quarter earnings report, CNBC reports. The pharmaceutical company says nearly 36,000 of the volunteers have already received the second of its two-dose COVID-19 vaccine. Pfizer has been working alongside German drugmaker BioNTech on the experimental vaccine. It contains genetic material called messenger RNA, or mRNA, which scientists hope provokes the immune system to fight the virus. 

• Drugmaker Eli Lilly is continuing to work on a potential COVID-19 treatment despite research showing that it may not work on hospitalized patients. The company said this morning it remains confident that its drug may stop COVID-19 from developing in other nonhospitalized patients. Researchers are still studying the drug in mild to moderately ill patients to try to prevent hospitalization and severe illness. Read the full story.

Advertisement

Read more stories on how the coronavirus is impacting the Baton Rouge business community. See a roundup of resources available to those impacted by the pandemic. Click here to see a 225 magazine list of local restaurants offering patio seating or indoor dining during phase three of reopening.   

Discussion (0)

From Our Partners

Daily Report Poll

ASK AI

Ask anything about Baton Rouge business